GlassScriptPhysician profile
William Clement Moss
NPI 1700996659
$882.06
in general payments reported to CMS, 2019-2025
14 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.52 · 2023: $107 · 2024: $444 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $348.40 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Merck Sharp & Dohme LLC | $111.51 | 2025 | Keytruda |
| Ethicon US, LLC | $67.29 | 2019-2024 | Vistaseal, Stratafix |
| Pacira Pharmaceuticals Incorporated | $59.90 | 2024-2025 | Exparel, Iovera, Zilretta |
| Vertex Pharmaceuticals Incorporated | $57.33 | 2024-2025 | |
| Veracyte, INC. | $43.27 | 2023 | |
| Focal Therapeutics, INC. | $34.04 | 2019 | |
| Nevro Corp. | $30.32 | 2023 | Senza |
| Hologic Sales and Service, LLC | $29.00 | 2024 | Localizer |
| Medtronic, INC. | $25.07 | 2025 | Progrip |
| Myriad Genetic Laboratories, INC. | $21.75 | 2025 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $19.12 | 2023 | Dysport |
| Davol INC. | $18.26 | 2024 | Arista Ah Flexitip |
| Elucent Medical | $16.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.